

Accepted Manuscript

Title: Grade II Acute GVHD and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Posttransplant Cyclophosphamide

Author: Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bolaños-Meade, Carol Ann Huff, Ivan Borrello, William H. Matsui, Robert A. Brodsky, Richard F. Ambinder, Maria P. Bettinotti, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik

PII: S1083-8791(17)30782-6
DOI: <https://doi.org/doi:10.1016/j.bbmt.2017.10.023>
Reference: YBBMT 54837


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 12-8-2017

Accepted date: 11-10-2017

Please cite this article as: Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bolaños-Meade, Carol Ann Huff, Ivan Borrello, William H. Matsui, Robert A. Brodsky, Richard F. Ambinder, Maria P. Bettinotti, Ephraim J. Fuchs, Gary L. Rosner, Richard J. Jones, Leo Luznik, Grade II Acute GVHD and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Posttransplant Cyclophosphamide, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/doi:10.1016/j.bbmt.2017.10.023>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Grade II Acute GVHD and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Posttransplant Cyclophosphamide

Shannon R. McCurdy,¹ Christopher G. Kanakry,¹ Hua-Ling Tsai,² Yvette L. Kasamon,¹ Margaret M. Showel,¹ Javier Bolaños-Meade,¹ Carol Ann Huff,¹ Ivan Borrello,¹ William H. Matsui,¹ Robert A. Brodsky,¹ Richard F. Ambinder,¹ Maria P. Bettinotti,³ Ephraim J. Fuchs,¹ Gary L. Rosner,² Richard J. Jones,¹ Leo Luznik¹

¹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.;

²Biostatistics & Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; ³Immunogenetics Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD, U.S.A.

Corresponding Author Shannon McCurdy, M.D. Corresponding author; CRB I, Room 3M88, 1650 Orleans Street, Baltimore, MD 21287; Phone 410-955-7035; Fax 410-367-2194; Email, smccurd2@jhmi.edu

Title Character Count: (limit 165) 163

Running heads/Short Title Character Count: 59

Abstract Word Count: 245

Figure Count: 8

Supplementary Figure Count: 2

References: 67

Presented in part at the 2014 ASH meeting, abstract #730

Short Title: Grade II Acute GVHD and Higher Graft Dose Improve Haplo BMT

Disclosure of Conflicts of Interest:

The authors have no potential conflicts of interest.

Highlights:

- **Grade II acute GVHD improves progression-free survival after haplo BMT**
- **Grade II acute GVHD decreases relapse after haplo BMT**
- **Higher nucleated cell graft dose improves survival after haplo BMT**
- **Higher nucleated cell graft dose decreases relapse and grade III-IV acute GVHD**

ABSTRACT

Download English Version:

<https://daneshyari.com/en/article/8430344>

Download Persian Version:

<https://daneshyari.com/article/8430344>

[Daneshyari.com](https://daneshyari.com)